Tekla Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Tekla Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-213,808	Closed	-$6.06M	–	217
2020 Q4	$6.06M	Buy	213,808 +127,968	+149%	+$3.31M	0.21%	109
2020 Q3	$2.16M	Hold	85,840	–	–	0.08%	152
2020 Q2	$2.1M	Hold	85,840	–	–	0.08%	158
2020 Q1	$1.27M	Hold	85,840	–	–	0.06%	162
2019 Q4	$1.39M	Buy	+85,840	New	+$1.33M	0.05%	170
2018 Q4	–	Sell	-77,919	Closed	-$1.94M	–	212
2018 Q3	$1.94M	Hold	77,919	–	–	0.07%	158
2018 Q2	$2.14M	Buy	77,919 +34,590	+80%	+$1.04M	0.08%	136
2018 Q1	$1.33M	Buy	43,329 +11,104	+34%	+$357K	0.05%	152
2017 Q4	$1.15M	Buy	+32,225	New	+$925K	0.04%	143
2016 Q4	–	Sell	-75,000	Closed	-$1.22M	–	150
2016 Q3	$1.22M	Hold	75,000	–	–	0.05%	131
2016 Q2	$1.02M	Buy	75,000 +30,000	+67%	+$530K	0.04%	145
2016 Q1	$786K	Buy	+45,000	New	+$916K	0.03%	133

Other funds holding RVNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Tekla Capital Management's RVNC Position: Q1 2021 in Review

Tekla Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2021, closing a stake of 213,808 shares — an estimated $6.06M sold.

Tekla Capital Management first reported a position in RVNC in Q1 2016 and held it in 12 quarters. The position peaked at $6.06M in Q4 2020. 149 funds tracked by Wall St. Rank hold RVNC as of Q1 2021.

Tekla Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
Tekla Capital Management sold 213,808 Revance Therapeutics, Inc. shares in Q1 2021, an estimated $6.06M.
Tekla Capital Management first reported a position in Revance Therapeutics, Inc. in Q1 2016 and held it in 12 quarters.
Tekla Capital Management's Revance Therapeutics, Inc. position peaked at $6.06M in Q4 2020.
149 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2021.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.